Lionco Pharm Grp Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 1.32%

Lionco Pharm Grp Co Ltd (603669) has an Asset Resilience Ratio of 1.32% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 603669 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥14.81 Million
≈ $2.17 Million USD Cash + Short-term Investments

Total Assets

CN¥1.12 Billion
≈ $164.14 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2015–2025)

This chart shows how Lionco Pharm Grp Co Ltd's Asset Resilience Ratio has changed over time. See Lionco Pharm Grp Co Ltd balance sheet quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Lionco Pharm Grp Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Lionco Pharm Grp Co Ltd stock valuation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥14.81 Million 1.32%
Total Liquid Assets CN¥14.81 Million 1.32%

Asset Resilience Insights

  • Limited Liquidity: Lionco Pharm Grp Co Ltd maintains only 1.32% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Lionco Pharm Grp Co Ltd Industry Peers by Asset Resilience Ratio

Compare Lionco Pharm Grp Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Aurobindo Pharma Limited
NSE:AUROPHARMA
Drug Manufacturers - Specialty & Generic 1.28%
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
Drug Manufacturers - Specialty & Generic -0.89%
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
Drug Manufacturers - Specialty & Generic 0.20%
Xeris Pharmaceuticals Inc
NASDAQ:XERS
Drug Manufacturers - Specialty & Generic 0.00%
Procter & Gamble Health Limited
NSE:PGHL
Drug Manufacturers - Specialty & Generic 33.01%

Annual Asset Resilience Ratio for Lionco Pharm Grp Co Ltd (2015–2025)

The table below shows the annual Asset Resilience Ratio data for Lionco Pharm Grp Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 1.20% CN¥13.32 Million
≈ $1.95 Million
CN¥1.11 Billion
≈ $161.96 Million
-1.28pp
2024-12-31 2.49% CN¥31.22 Million
≈ $4.57 Million
CN¥1.26 Billion
≈ $183.69 Million
-21.56pp
2023-12-31 24.04% CN¥390.59 Million
≈ $57.16 Million
CN¥1.62 Billion
≈ $237.72 Million
+3.05pp
2022-12-31 20.99% CN¥389.51 Million
≈ $57.00 Million
CN¥1.86 Billion
≈ $271.51 Million
-2.04pp
2021-12-31 23.03% CN¥579.13 Million
≈ $84.74 Million
CN¥2.51 Billion
≈ $367.93 Million
+16.41pp
2020-12-31 6.63% CN¥180.00 Million
≈ $26.34 Million
CN¥2.72 Billion
≈ $397.47 Million
-11.97pp
2019-12-31 18.59% CN¥355.78 Million
≈ $52.06 Million
CN¥1.91 Billion
≈ $280.00 Million
+2.88pp
2018-12-31 15.72% CN¥325.00 Million
≈ $47.56 Million
CN¥2.07 Billion
≈ $302.60 Million
-14.56pp
2017-12-31 30.27% CN¥500.00 Million
≈ $73.17 Million
CN¥1.65 Billion
≈ $241.69 Million
-6.93pp
2016-12-31 37.20% CN¥500.00 Million
≈ $73.17 Million
CN¥1.34 Billion
≈ $196.67 Million
-7.46pp
2015-12-31 44.66% CN¥600.00 Million
≈ $87.80 Million
CN¥1.34 Billion
≈ $196.60 Million
--
pp = percentage points

About Lionco Pharm Grp Co Ltd

SHG:603669 China Drug Manufacturers - Specialty & Generic
Market Cap
$494.08 Million
CN¥3.38 Billion CNY
Market Cap Rank
#12499 Global
#3715 in China
Share Price
CN¥4.74
Change (1 day)
+0.21%
52-Week Range
CN¥4.05 - CN¥6.97
All Time High
CN¥12.67
About

Lionco Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products and medical services in China. It offers chemical and prescription drugs for nutrition, antimicrobial, antiviral, digestive, cardiovascular, cerebrovascular, detoxification, anti-tumor, and other applications. The company was founded in 2003 a… Read more